New anti-CKAP4 antibodies deliver hope for pancreatic cancer treatment

Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, including pancreatic cancer. On the basis of an antibody derived from mice, the researchers developed an antibody that could be used in humans (Hv1Lt1). Hv1Lt1 successfully prevented tumor formation in experimental mice. When given in combination, it improved the effect of chemotherapy drugs.